Wire · founder news, decoded · opportunities
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics won FDA accelerated approval for TRUTAKNA (atacicept-vymj), the first BAFF/APRIL inhibitor for IgA nephropathy, based on 46% proteinuria reduction in Phase 3 trials. The company is launching with 82 nephrology-focused sales reps and a $425,000 annual list price, targeting 6,000 nephrologists serving ~160,000 US patients.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you sell into nephrology or rare kidney disease, Vera just opened a 6,000-doctor market that was untreated until today — and they've already hired the 82 reps and set the payer conversations. Your window to partner or sell into their launch is the next 90 days, before ORIGIN 3 confirmatory data locks the market position.
Read the full story at tradingview.com →
Topics: Digital Health · fda-approval · rare-disease · commercial-launch · nephrology · immunology